From the Nasdaq MarketSite Studio, New to The Street’s TV Host Jane King talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) (“Company”), a late-stage biopharmaceutical company that publicly trades on the NASDAQ market. ACXP is developing a new class of small molecular antibiotics for the most common life-threatening bacterial infections. Recently, the Company completed its FDA Phase 2 clinical trials on its Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Management is now meeting with the FDA regarding the steps necessary to complete the Phase 3 clinical trial on the drug. Concurrently, ACXP is meeting with the FDA on the manufacturing processes of the drug, which needs to meet the government’s standards. Management remains confident that Ibezapolstat can be manufactured and inventoried before the conclusion of 2024. The United States Patent and Trademark Office (USPTO) has issued a patent because the drug can, in treated patients, maintain and restore microbiome bacteria. Most pharmaceuticals destroy the gut’s microbiome bacteria which is the major cause of diseases and reinfections, typically from competitor drugs for CDI. The issued patent remains valid until June 2042. The Company is working globally with several entities seeking partnerships and other collaborations on non-dilutive financing arrangements for the funding needs of the FDA Phase 3. The objective is to get funded without using ACXP’s stock, which will not dilute shareholders’ value. David started a program to work with college students, being a mentor to assist students in bringing their scientific ideas to market. With the FDA and USPTO continuing to provide timely approvals, the Company has shown that its Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. – https://www.acurxpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
About New to the Street: https://newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list